MentionFox
Home › Executive changes › Bionano Genomics, Inc.
Leadership changes · SEC Form 8-K, Item 5.02

Bionano Genomics, Inc. executive changes

Every leadership change Bionano Genomics, Inc. reported to the SEC under Item 5.02: who left, who was appointed, to what role and from when, quoted from each filing.

Filings2
Appointments named1
Departures named1
Latest filing2026-06-05

Bionano Genomics, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-06-05. Between them they name 2 people, with 1 appointment and 1 departure. Each change below is quoted from the filing and linked to it.

Every change, newest first

Filed 2026-06-05 · 8-K

Reported

On June 2, 2026, Alka Chaubey, Ph.D. resigned as Chief Medical Officer of Bionano Genomics, Inc. (the "Company") effective July 5, 2026.
Filed 2026-05-06 · 8-K

Departing: R. Erik Holmlin

In connection with his termination, Dr. Holmlin resigned from the Company's Board of Directors (the "Board") and any committees thereof, effective as of the Effective Date.

Appointed: Albert A. Luderer, Chief Executive Officer

As of the Effective Date, the Board appointed Albert A. Luderer, Ph.D., who currently serves as the Company's Chairman of the Board, as the Company's Interim Chief Executive Officer.
Hiring for a seat like this?

Find people with the same kind of experience as the Chief Executive Officer at Bionano Genomics, Inc., with the record behind each one.

Find candidates like Chief Executive Officer at Bionano Genomics, Inc.
Selling to Bionano Genomics, Inc.?

New leaders review vendors and budgets in their first months. Get an alert the next time Bionano Genomics, Inc. is in the news or changes leadership.

Get an alert when Bionano Genomics, Inc. changes leadership

Tools for this story

Each opens in a new tab, filled in for Bionano Genomics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/bionano-genomics
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2
Bionano Genomics, Inc. (BNGO) executive changes: 2 leadership filings. MentionFox, 2026-09-27. https://mentionfox.com/executive-changes/bionano-genomics